BIOCRYST PHARMACEUTICALS, INC. Selling, General and Administrative Expense
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Selling, General and Administrative Expense of $63.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $63.98M, a 26.79% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $94.55M, a 14.65% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $95.78M, a 18.97% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $83.01M, a 27.52% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $348.65M, a 30.90% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $266.35M, a 24.42% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $214.07M, a 34.32% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $159.37M, a 34.13% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $63.98M 10-Q · filed 2026-08-05 | $158.53M 10-Q · filed 2026-08-05 | $254.31M derived: sum of 3 quarters · filed 2026-08-05 | $337.32M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $94.55M 10-Q · filed 2026-05-06 | $190.34M derived: sum of 2 quarters · filed 2026-05-06 | $273.35M derived: sum of 3 quarters · filed 2026-05-06 | $360.73M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $95.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $178.79M derived: sum of 2 quarters · filed 2026-02-26 | $266.18M derived: sum of 3 quarters · filed 2026-08-05 | $348.65M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $83.01M 10-Q · filed 2025-11-04 | $170.40M derived: sum of 2 quarters · filed 2026-08-05 | $252.87M 10-Q · filed 2025-11-04 | $333.37M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $87.38M 10-Q · filed 2026-08-05 | $169.85M 10-Q · filed 2026-08-05 | $250.36M derived: sum of 3 quarters · filed 2026-08-05 | $315.46M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $82.47M 10-Q · filed 2026-05-06 | $162.98M derived: sum of 2 quarters · filed 2026-05-06 | $228.08M derived: sum of 3 quarters · filed 2026-05-06 | $289.33M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $80.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $145.61M derived: sum of 2 quarters · filed 2026-02-26 | $206.86M derived: sum of 3 quarters · filed 2026-02-26 | $266.35M 10-K · filed 2026-02-26 | $266.13M 10-K · filed 2025-02-25 | |||
| 2024-09-30 | $65.10M 10-Q · filed 2025-11-04 | $65.08M 10-Q · filed 2024-11-05 | $126.35M derived: sum of 2 quarters · filed 2025-11-04 | $185.84M 10-Q · filed 2025-11-04 | $185.66M 10-Q · filed 2024-11-05 | $250.40M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $61.25M 10-Q · filed 2025-08-05 | $61.21M 10-Q · filed 2024-08-06 | $120.74M 10-Q · filed 2025-08-05 | $120.58M 10-Q · filed 2024-08-06 | $185.30M derived: sum of 3 quarters · filed 2026-02-26 | $235.95M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $59.49M 10-Q · filed 2025-05-06 | $59.36M 10-Q · filed 2024-05-07 | $124.05M derived: sum of 2 quarters · filed 2026-02-26 | $174.70M derived: sum of 3 quarters · filed 2026-02-26 | $225.70M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $64.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.21M derived: sum of 2 quarters · filed 2026-02-26 | $166.21M derived: sum of 3 quarters · filed 2026-02-26 | $214.07M 10-K · filed 2026-02-26 | $213.89M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $50.65M 10-Q · filed 2024-11-05 | $101.64M derived: sum of 2 quarters · filed 2024-11-05 | $149.51M 10-Q · filed 2024-11-05 | $199.66M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $51.00M 10-Q · filed 2024-08-06 | $98.86M 10-Q · filed 2024-08-06 | $149.02M derived: sum of 3 quarters · filed 2025-02-25 | $185.94M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $47.87M 10-Q · filed 2024-05-07 | $98.02M derived: sum of 2 quarters · filed 2025-02-25 | $134.94M derived: sum of 3 quarters · filed 2025-02-25 | $172.96M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $50.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $87.07M derived: sum of 2 quarters · filed 2025-02-25 | $125.09M derived: sum of 3 quarters · filed 2025-02-25 | $159.37M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $36.92M 10-Q · filed 2023-11-08 | $74.94M derived: sum of 2 quarters · filed 2023-11-08 | $109.22M 10-Q · filed 2023-11-08 | $144.60M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $38.02M 10-Q · filed 2023-08-07 | $72.30M 10-Q · filed 2023-08-07 | $107.69M derived: sum of 3 quarters · filed 2024-02-27 | $142.68M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $34.28M 10-Q · filed 2023-05-08 | $69.67M derived: sum of 2 quarters · filed 2024-02-27 | $104.66M derived: sum of 3 quarters · filed 2024-02-27 | $130.99M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $35.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $70.38M derived: sum of 2 quarters · filed 2024-02-27 | $96.70M derived: sum of 3 quarters · filed 2024-02-27 | $118.82M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $34.99M 10-Q · filed 2022-11-04 | $61.32M derived: sum of 2 quarters · filed 2022-11-04 | $83.43M 10-Q · filed 2022-11-04 | $104.42M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $26.32M 10-Q · filed 2022-08-05 | $48.44M 10-Q · filed 2022-08-05 | $69.42M derived: sum of 3 quarters · filed 2023-02-27 | $86.62M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $22.11M 10-Q · filed 2022-05-09 | $43.10M derived: sum of 2 quarters · filed 2023-02-27 | $60.30M derived: sum of 3 quarters · filed 2023-02-27 | $74.18M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $20.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $38.18M derived: sum of 2 quarters · filed 2023-02-27 | $52.06M derived: sum of 3 quarters · filed 2023-02-27 | $67.93M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $17.20M 10-Q · filed 2021-11-04 | $31.08M derived: sum of 2 quarters · filed 2021-11-04 | $46.94M 10-Q · filed 2021-11-04 | $57.43M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $13.88M 10-Q · filed 2021-08-09 | $29.75M 10-Q · filed 2021-08-09 | $40.24M derived: sum of 3 quarters · filed 2022-02-28 | $51.97M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $15.87M 10-Q · filed 2021-05-07 | $26.35M derived: sum of 2 quarters · filed 2022-02-28 | $38.09M derived: sum of 3 quarters · filed 2022-02-28 | $46.75M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $10.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $22.22M derived: sum of 2 quarters · filed 2022-02-28 | $30.88M derived: sum of 3 quarters · filed 2022-02-28 | $37.12M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $11.73M 10-Q · filed 2020-11-06 | $20.39M derived: sum of 2 quarters · filed 2020-11-06 | $26.63M 10-Q · filed 2020-11-06 | $31.12M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $8.66M 10-Q · filed 2020-08-07 | $14.90M 10-Q · filed 2020-08-07 | $19.39M derived: sum of 3 quarters · filed 2021-03-01 | $27.31M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $6.24M 10-Q · filed 2020-05-11 | $10.73M derived: sum of 2 quarters · filed 2021-03-01 | $18.65M derived: sum of 3 quarters · filed 2021-03-01 | $28.14M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $12.41M derived: sum of 2 quarters · filed 2021-03-01 | $21.91M derived: sum of 3 quarters · filed 2021-03-01 | $29.51M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $7.92M 10-Q · filed 2019-11-08 | $17.41M derived: sum of 2 quarters · filed 2019-11-08 | $25.02M 10-Q · filed 2019-11-08 | $29.72M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-06-30 | $9.49M 10-Q · filed 2019-08-08 | $17.10M 10-Q · filed 2019-08-08 | $21.80M derived: sum of 3 quarters · filed 2020-03-13 | $25.14M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-03-31 | $7.61M 10-Q · filed 2019-05-09 | $12.31M derived: sum of 2 quarters · filed 2020-03-13 | $15.65M derived: sum of 3 quarters · filed 2020-03-13 | $18.48M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2017-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $8.04M derived: sum of 2 quarters · filed 2020-03-13 | $10.88M derived: sum of 3 quarters · filed 2020-03-13 | $13.93M 10-K · filed 2020-03-13 | ||||
| 2017-09-30 | $3.34M 10-Q · filed 2018-11-08 | $6.18M derived: sum of 2 quarters · filed 2018-11-08 | $9.23M 10-Q · filed 2018-11-08 | $11.80M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $2.83M 10-Q · filed 2018-08-09 | $5.89M 10-Q · filed 2018-08-09 | $8.45M derived: sum of 3 quarters · filed 2019-03-14 | $11.21M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $3.06M 10-Q · filed 2018-05-09 | $5.62M derived: sum of 2 quarters · filed 2019-03-14 | $8.38M derived: sum of 3 quarters · filed 2019-03-14 | $11.10M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $5.32M derived: sum of 2 quarters · filed 2019-03-14 | $8.04M derived: sum of 3 quarters · filed 2019-03-14 | $11.25M 10-K · filed 2019-03-14 | ||||
| 2016-09-30 | $2.76M 10-Q · filed 2017-11-08 | $5.48M derived: sum of 2 quarters · filed 2017-11-08 | $8.69M 10-Q · filed 2017-11-08 | $11.41M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $2.72M 10-Q · filed 2017-08-08 | $5.94M 10-Q · filed 2017-08-08 | $8.66M derived: sum of 3 quarters · filed 2018-03-12 | $11.39M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $3.21M 10-Q · filed 2017-05-08 | $5.93M derived: sum of 2 quarters · filed 2018-03-12 | $8.66M derived: sum of 3 quarters · filed 2018-03-12 | $12.20M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2015-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $5.45M derived: sum of 2 quarters · filed 2018-03-12 | $8.99M derived: sum of 3 quarters · filed 2018-03-12 | $13.05M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $2.73M 10-Q · filed 2016-11-08 | $6.26M derived: sum of 2 quarters · filed 2016-11-08 | $10.33M 10-Q · filed 2016-11-08 | |||||
| 2015-06-30 | $3.53M 10-Q · filed 2016-08-08 | $7.59M 10-Q · filed 2016-08-08 | ||||||
| 2015-03-31 | $4.06M 10-Q · filed 2016-05-09 | |||||||
| 2014-12-31 | $7.46M 10-K · filed 2017-02-27 | |||||||
| 2013-12-31 | $6.01M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |